HCW Biologics

#ViewsMilestone #Immunotheray #antiAging So excited to share the news that our paper published in Aging Cell, Immunotherapeutic approach to reduce senescent cells and alleviate senescence‐associated secretory phenotype in mice, has received over 4,000 views*. Now that’s something to celebrate! 🎉 👏 Shrestha N, et al. Aging Cell. 2023 May;22(5):e13806. doi: 10.1111/acel.13806. Epub 2023 Mar 26. PMID: 36967480; PMCID: PMC10186597. ⭐ ⭐ ⭐ ⭐ ⭐ Here is the link to the paper: https://lnkd.in/egTBZGMa

HCW Biologics UMN-Sponsored Phase 1 Study: Preliminary Human Data Readout from 2023 SITC 👍 🎉 HCW9218 was administered subcutaneously once every three weeks for up to six cycles at dose levels 0.25 mg/kg (DL1), 0.5 mg/kg (DL2), 0.8 mg/kg (DL3) or 1.2 mg/kg (DL4). The median number of cycles was three. 87% (13/15) had >4 lines of prior therapy. Tumor types included: Ovarian (n=6), Colorectal (n=4), Rectal (n=3), and Liver (n=2). 53% (8/15) patients treated with HCW9218 were evaluated in a post-treatment assessment, including biopsies and scanning. Tumor types included: Ovarian (n=3), Colorectal (n=3), Rectal (n= 1) and Liver (n=1). 50% (4/8) patients evaluated in post-treatment assessments exhibited stable disease following HCW9218 treatment. Patients showed stable disease lasting over 6 months. Clinical benefit was observed from DL2, DL3 and DL4. 66% (2/3) patients with ovarian cancer who underwent post-treatment assessments showed stable disease. https://lnkd.in/gwQPawGp

🎉🎉 MASONIC CANCER CENTER, UNIVERSITY OF MINNESOTA TO PRESENT DATA IN POSTER PRESENTATION HUMAN DATA READOUT FOR PHASE 1 STUDY TO EVALUATE HCW9218 IN SOLID TUMORS AT SITC 38TH ANNUAL MEETING HCW Biologics Inc. will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota. The poster will be presented by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota, a Principal Investigator for this study. Title: Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors Presentation Type: Poster 767 Presenter: Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota Location: Exhibit Halls A and B1 – San Diego Convention Center Date/Time: Friday, November 3, 2023, 9 a.m.–7 p.m. Pacific time. The presentation will be available on the Company’s website in the Investors section under Events & Presentations, following the conference. To read more: https://lnkd.in/gZn4Dbau